Asthma and COPD Drugs Market – Global Opportunity Analysis and Industry Forecast, 2017-2022
Asthma and COPD Drugs Market by Disease (COPD and Asthma) by Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics and Others) - Global Opportunity Analysis and Industry Forecasts, 2014-2022
- Report Number: 180910909
The Global Asthma and COPD Drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Asthma is a chronic respiratory disease blocking the airways of lung because of inflammation, mucus production, tighten of muscles. Chronic Obstructive Pulmonary Disease(COPD) is caused by obstruction in the airways causing difficulty in breathing, with the primary cause as tobacco smoking.
Symptoms of Asthma and COPD
This report covers information on various types of medication class to treat asthma and COPD in compliance with the European Medical Association (EMA), the U.S. Food and Drugs Administration (FDA), Conformité Européene (CE) and other regulatory authorities. Moreover, this study on the global Asthma and COPD Drugs also focuses on the treatment of the disease which is available in the market.
The Global Asthma and COPD Drugs market is segmented based on disease, medication class and geography. Based on disease, the market is categorized into asthma and COPD. Based on medication class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Based on geography, the market is categorized into North America, Europe, Asia-Pacific, and LAMEA. North America holding major share of the market.
Asthma and COPD Drugs Market Segmentation
The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of this market. The market is driven by the growing patient COPD and asthmatic population, as well as FDA approvals for the novel products and its wide acceptance among the patient population. Increasing government initiatives to control COPD and asthma further fuel the growth for this market.
The Asthma and COPD Drug market consists of medication class based on the severity of the disease. Short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids(ICS), leukotriene antagonists (LTA), combination products, anticholinergics and others are the medication class which are used in the treatment of COPD and asthma.
The disease segment consists of the global prevalence of asthma and COPD for market sizing and forecasting the global sales of the Asthma and COPD Drugs. Asthma contributed the highest share, approximately 66.1%, to the world Asthma and COPD Drugs market with the expected to grow at a highest CAGR of 1.3% by 2022.
The growth of the North American and European market is driven by the increasing COPD and asthma patient population and rising number of smokers. North American Asthma and COPD Drugs market is likely to register a CAGR of 3.2% over the analysis period, which would create potential opportunities for new market players to grow.
Top impacting factors
Increase in prevalence of COPD and asthma patients; increase in world ageing population, technological advancement in the treatment of asthma and COPD, increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness are the major factors that drive the growth of the Asthma and COPD Drug.
However, stringent government regulatory requirement for the approval of asthma and COPD drugs, the asthma and COPD drugs showing side effects, patent expiry of the drugs restrict the market growth. Furthermore, developing countries, such as China and India, provide huge growth opportunities along with introduction of generic drugs to this market.
The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players. The major players profiled in this report include GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer (U.S).
Other players in the value chain include Mylan, Aerovance Inc. Alkermes Inc. Almirall SA. Genentech Inc. Sepracor, Inc. Skyepharma plc.
Asthma and COPD Drugs Market Key benefits
- The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
- The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
- Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
- Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
ASTHMA AND COPD DRUGS MARKET KEY SEGMENTS
By Medication Class
- Combination Products
- Relvar/Breo Ellipta
- Leukotriene Antagonists (LTA)
- Inhaled Corticosteroids (ICS)
- Short Acting Beta Agonists(SABA)
- Long Acting Beta Agonists (LABA)
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Middle East
Table of Content
Chapter: 1 INTRODUCTION
1.1 Report description
1.4.1 Secondary research
Chapter: 2 EXECUTIVE SUMMARY
2.1 CXO perspective
Chapter: MARKET OVERVIEW
3.1 Market definition and scope
3.2.1 Top investment pockets
3.3 Porters five forces analysis
3.3.1 Bargaining power of buyers (High)
3.4 Market dynamics
18.104.22.168 Increasi in number of asthmatic and COPD patients worldwide
22.214.171.124 Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs
126.96.36.199 Inrtoduction of generic drugs of asthma and COPD drugs
3.5 Market share analysis, 2015
Chapter: 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE
4.2.1 Global prevalence
4.3.1 Global prevalence
Chapter: 5 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS
5.2.1 Market size and forecast
5.3 Leukotriene antagonists (LTA)
5.3.1 Market size and forecast
5.4 Inhaled corticosteroids (ICS)
5.4.1 Market size and forecast
5.5.1 Market size and forecast
5.6 Short acting beta agonists (SABA)
5.6.1 Market size and forecast
5.7 Long acting beta agonists (LABA)
5.7.1 Market size and forecast
5.8.1 Market size and forecast
Chapter: 6 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key market trends
6.3.1 Key market trends
6.4.1 Key market trends
6.5.1 Key market trends
Chapter: 7 GLOBAL ASTHMA AND COPD DRUGS PIPELINE -2015
Chapter: 8 COMPANY PROFILES
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company overview
8.2 Merck & Co., Inc.
8.2.1 Company overview
8.3 GlaxoSmithKline PLC.
8.3.1 Company overview
8.4 Novartis AG
8.4.1 Company overview
8.5.1 Company overview
8.6 F. Hoffmann-La Roche Ltd
8.6.1 Company overview
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company overview
8.8 Vectura Group plc.
8.8.1 Company overview
8.9 Pfizer, Inc.
8.9.1 Company overview
8.10 Abbott Laboratories
8.10.1 Company overview
List of Figures
FIG. 1 TOP INVESTMENT POCKETS IN GLOBALASTHMA AND COPD DRUGS MARKET
List of Tables
TABLE 1 ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
With collective industry experience of about 200 years of its analysts and experts, Future Industry Insight (FII) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With FII’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
Future Industry Insight (FII) has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, FII’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.